Raichur: Shilpa Medicare Limited, recently announced that its Investigational New Drug (IND), Nor-Ursodeoxycholic Acid ...

The trials identified no serious adverse effects, and patients tolerated a daily dosage of 1500 mg for 24 weeks.

Shilpa Medicare announces the approval of its IND - Nor Ursodeoxycholic Acid Tablets 500 mg, by the Subject Expert Committee of CDSCO. The Committee has further recommended grant of marketing ...

Non-alcoholic fatty liver disease (NAFLD) affects nearly 19 crore people in India and about a quarter of the world’s ...

The spike in Shilpa Medicare's stock price came after the company announced the approval of its Investigational New Drug (IND ...

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission.

Licensed therapies include ursodeoxycholic acid (UDCA) and obeticholic acid (OCA), alongside experimental new and re-purposed agents. Disease management focuses on initiation of UDCA for all patients ...

Therefore, the patient was diagnosed with IRH, and the PD-1 inhibitor tislelizumab was interrupted. The patient continued to receive ursodeoxycholic acid (UDCA) and was administered intravenous pulse ...

Regular tablets, like the iPad Mini, also make a great reading companion thanks to its bright display and access to multiple library apps. Ultimately, our testing considers all aspects of a ...

After selling out in barely 48 hours when it launched earlier this month, Lenovo has re-stocked the Legion Tab, its small yet powerful Android tablet. The Lenovo Legion Tab was announced at CES as ...